Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
CA2360319 A1 2000-08-17 [CA2360319] / 2000-08-17
申请号/申请日
2000CA-2360319 / 2000-02-09
发明人
HEALEY JOHN H;DIRESTA GENE R;
申请人
MEMORIAL SLOAN KETTERING CANCER CENTER;
主分类号
IPC分类号
A61K-031/5575A61K-031/565A61K-033/24A61K-038/00A61K-045/00A61L-024/00A61L-027/00A61L-027/54
摘要
(CA2360319) Anti-resorptive bone cements, comprising an anti-resorptive amount of one or more anti-resorptive agents, preferably the anti-resorptive agent is a bisphosphonate.  The anti-resorptive bone cements are useful for reducing bon e voids and bonding prosthetic devices to bone.  The invention also relates to anti-resorptive allogeneic, autografic, and xenografic bone grafts, which bo ne grafts comprise an anti-resorptive amount of an anti-resorptive agent such a s a bisphosphonate.  The anti-resorptive bone grafts are useful for reconstructive bone surgery.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
1999US-60119260 1999-02-09 2000WO-US03285 2000-02-09
主权利要求
(CA2360319)  WHAT IS CLAIMED IS: 1. A moldable composition comprising (a) a bone cement material selected from the group consisting of an organic bone-cement dough, an inorganic bonecement dough, and a composite bone-cement dough;  and (b) an anti-resorptive amount of an antiresorptive agent. 2. The composition of claim 1, wherein the anti-resorptive agent is selected from the group consisting of a bisphosphonate, a pharmaceutically acceptable salt or ester thereof, a salt of a Group IIIA element, a cholesterol lowering agent, and an estrogen-bisphosphonate conjugate. 3. The composition of claim 1, wherein the bone-cement dough is an acrylic bone-cement dough or a hydroxyapatite bone-cement dough. 4. The composition of claim 1, wherein the anti-resorptive agent is a gallium salt selected from the group consisting of gallium nitrate, gallium chloride, gallium fluoride, gallium sulfate, and gallium citrate. 5. The composition of claim 1, wherein the bone-cement dough is an acrylic bone-cement dough and the anti-resorptive agent is a bisphosphonate selected from the group consisting of pamidronate, etidronate, and alendronate or a pharmaceutically acceptable salt or ester thereof. 6. The composition of claim 5, wherein the acrylic bone-cement dough comprises polymethyl methacrylate. 7. The composition of claim 1, wherein the anti-resorptive agent is on a surface of the bone-cement dough. 8. The composition of claim 1, wherein the anti-resorptive agent is impregnated in the bone-cement dough. 9. A moldable composition comprising (a) a bone-cement dough selected from the group consisting of an organic bone-cement dough, an inorganic bone-cement dough, and a composite bone-cement dough and (b) an anti-resorptive amount of a proteinaceous or a hormonal anti-resorptive agent. 10. The composition of claim 9, wherein the anti-resorptive agent is on a surface of the bone-cement dough. 11. The composition of claim 9, wherein the anti-resorptive agent is impregnated in the bone-cement dough. 12. The composition of claim 9, wherein the proteinaceous or hormonal antiresorptive agent is selected from the group consisting of an estrogen, a prostaglandin, and a cytokine. 13. A moldable composition comprising (a) a bone-cement dough selected from the group consisting of an organic bone-cement dough, an inorganic bone-cement dough, and a composite bone-cement dough and (b) a pharmaceutically effective amount of a bone-formative agent. 14. The composition of claim 13, wherein the bone-formative agent is on a surface of the bone-cement dough. 15. The composition of claim 13, wherein the bone-formative agent is impregnated in the bone-cement dough. 16. The composition of claim 13, wherein the bone-formative agent is selected from the group consisting of OP-1, BMP-2, BMP-3, BMP-4, LMP-1, and BMP-1. 17. An ex-vivo bone graft impregnated with an anti-resorptive amount of an anti-resorptive agent. 18. The bone graft of claim 17, wherein the anti-resorptive agent is selected from the group consisting of a bisphosphonate, a pharmaceutically acceptable salt or ester thereof, a salt of a Group IIIA element, a cholesterol lowering agent, a chemotherapeutic agent-bisphosphonate conjugate, and an estrogen-bisphosphonate conjugate. 19. The bone graft of claim 17, wherein the bone is selected from the group consisting of an allogeneic bone graft, an autografic bone graft, or a xenografic bone graft. 20. The bone graft of claim 17, wherein the bisphosphonate is selected from the group consisting of pamidronate, etidronate, and alendronate, or a pharmaceutically acceptable salt or ester thereof. 21. The bone graft of claim 17, wherein the anti-resorptive agent is a gallium salt. 22. The bone graft of claim 21, wherein the gallium salt is selected from the group consisting of gallium nitrate, gallium chloride, gallium fluoride, gallium sulfate, and gallium citrate. 23. A method of making a moldable anti-resorptive bone cement, comprising contacting a bone cement material selected from the group consisting of an inorganic bonecement dough, an organic bone-cement dough, and a composite bone-cement dough with an anti-resorptive amount of an anti-resorptive agent 24. The method of claim 23, wherein the anti-resorptive agent is selected from the group consisting of a bisphosphonate, a pharmaceutically acceptable salt or ester thereof, a salt of a Group IIIA element, a cholesterol lowering agent, a chemotherapeutic agent-bisphosphonate conjugate, and an estrogen-bisphosphonate conjugate. 25. The method of claim 23, wherein the bone-cement dough is an organic bonecement dough and the anti-resorptive agent is a bisphosphonate. 26. A method of making a moldable anti-resorptive bone-cement dough, comprising contacting an organic bone-cement dough, an inorganic bone-cement dough, or a composite bone-cement dough with an anti-resorptive amount of a proteinaceous or hormonal anti-resorptive agent or with a pharmaceutically effective amount of a boneformative agent. 27. A method of making a moldable anti-resorptive bone-cement dough, comprising (a) admixing a polymer component with an anti-resorptive amount of an antiresorptive agent for form a mixture;  and (b) adding a liquid monomer component to the mixture. 28. The method of claim 27, wherein the polymer component comprises polymethyl methacrylate and the liquid monomer component comprises methyl methacrylate. 29. A method of making an anti-resorptive bone graft comprising contacting a bone graft selected from the group consisting of an allogeneic bone graft, an autografic bone graft, and a xenografic bone graft, with a fluid vehicle comprising an anti-resorptive amount of an anti-resorptive agent. 30. The method of claim 29, wherein the anti-resorptive agent is selected from the group consisting of a bisphosphonate, a pharmaceutically acceptable salt or ester thereof, a salt of a Group IIIA element, a cholesterol lowering agent, a chemotherapeutic agent-bisphosphonate conjugate, and an estrogen-bisphosphonate conjugate. 31. The composition of claim 1, further comprising a chemotherapeutic agent. 32. The composition of claim 31, wherein the anti-resorptive agent is a bisphosphonate. 33. The composition of claim 32, wherein the chemotherapeutic agent and the bisphosphonate are in the form of a bisphosphonate-chemotherapeutic agent conjugate. 34. The composition of claim 33, wherein the chemotherapeutic agent is doxorubicin or methotrexate. 35. The composition of claim 34, wherein the bisphosphonate is pamidronate. 36. A method for reducing a bone void in a patient in need thereof, comprising adding to the void an amount of the composition of claim 1 sufficient to reduce the void. 37. The method of claim 36, wherein the bone cement comprises polymethyl methacrylate and the anti-resorptive agent is a bisphosphonate.
法律状态
(CA2360319) LEGAL DETAILS FOR CA2360319  Actual or expected expiration date=2010-02-09    Legal state=DEAD    Status=LAPSED     Event publication date=2000-02-09  Event code=CA/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=CA CA2360319  Application date=2000-02-09  Standardized application number=2000CA-2360319     Event publication date=2000-08-17  Event code=CA/A1  Event type=Examination events  Application laid open  Publication country=CA  Publication number=CA2360319  Publication stage Code=A1  Publication date=2000-08-17  Standardized publication number=CA2360319     Event publication date=2005-02-07  Event code=CA/EEER  Event indicator=Pos  Event type=Examination events  Examination request    Event publication date=2010-02-09  Event code=CA/FZDE  Event indicator=Neg  Event type=Event indicating Not In Force  Dead
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部